Table 2 Clinical outcomes
Azvudine (n = 14) | Nirmatrelvir/ritonavir (n = 18) | SOC (n = 23) | |
|---|---|---|---|
Progressing to severe symptoms, n (%) | 0 | 0 | 2 (8.7%) |
NANC time (days), median (range) | |||
Symptom onset to NANC | 14 (6–25) | 15 (11–24) | 19 (18–23) |
Diagnosis to NANC | 14 (6–25) | 14.5 (11–24) | 17 (10–22) |
Hospital admission to NANC | 9 (4–22) | 12 (8–19) | 15 (10–22) |
Drug administration to NANC | 8 (4–20) | 9 (5–16) | NA |
Length of stay | 10.5 (5–23) | 13.5 (10–21) | 17 (10–23) |
NANC rate from admission, % (95% CI) | |||
Within 5 days | 14.3 (0.0,30.8) | 0 | 0 |
Within 7 days | 21.4 (0.0,40.2) | 0 | 0 |
Within 10 days | 57.1 (21.5,76.6) | 27.8 (3.8,45.8) | 17.4 (0.35,31.5) |
Within 14 days | 71.4 (34.6,87.5) | 83.3 (53.2,94.0) | 43.5 (19.1,60.5) |